Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Cassava Sciences, Inc.
Cassava Sciences, Inc. News
Cassava Sciences, Inc. Quantitative Score
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Cassava Sciences, Inc. Financials
Table Compare
Compare SAVA metrics with: | |||
|---|---|---|---|
Earnings & Growth | SAVA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SAVA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SAVA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SAVA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Cassava Sciences, Inc. Income
Cassava Sciences, Inc. Balance Sheet
Cassava Sciences, Inc. Cash Flow
Cassava Sciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Cassava Sciences, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.7500 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2012-12-24 | 0.75 | Quarterly |
| TBA | 2 | Quarterly |
Historical Market Cap
Shares Outstanding
Cassava Sciences, Inc. Executives
| Name | Role |
|---|---|
| Mr. Eric J. Schoen | Chief Financial Officer |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer |
| Mr. Richard Jon Barry | Chief Executive Officer, President & Director |
| Jaren Landen | Chief Clinical Development Officer |
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Eric J. Schoen | Chief Financial Officer | Male | 1968 | 725K |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer | Male | 1964 | 425K |
| Mr. Richard Jon Barry | Chief Executive Officer, President & Director | Male | 1959 | 319.38K |
| Jaren Landen | Chief Clinical Development Officer | -- | ||
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience | -- |
Cassava Sciences, Inc. Insider Trades
| Date | 23 May |
| Name | SCANNON PATRICK J MD PHD |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26500 |
| Date | 23 May |
| Name | Anderson Robert Eugene Jr |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26500 |
| Date | 23 May |
| Name | Gravier Pierre |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26500 |
| Date | 23 May |
| Name | GUSSIN ROBERT Z |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26500 |
| Date | 23 May |
| Name | Nicaise Claude |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26500 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 May | SCANNON PATRICK J MD PHD | Director | Acquired | A-Award | 26500 |
| 23 May | Anderson Robert Eugene Jr | Director | Acquired | A-Award | 26500 |
| 23 May | Gravier Pierre | Director | Acquired | A-Award | 26500 |
| 23 May | GUSSIN ROBERT Z | Director | Acquired | A-Award | 26500 |
| 23 May | Nicaise Claude | Director | Acquired | A-Award | 26500 |